| 13.49 0.98 (7.83%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.36 |
1-year : | 27.28 |
| Resists | First : | 20 |
Second : | 23.36 |
| Pivot price | 9.35 |
|||
| Supports | First : | 11.65 |
Second : | 6.5 |
| MAs | MA(5) : | 11.83 |
MA(20) : | 9.08 |
| MA(100) : | 28.75  |
MA(250) : | 0 | |
| MACD | MACD : | -1.7 |
Signal : | -3 |
| %K %D | K(14,3) : | 85.7 |
D(3) : | 77.9 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 65.8 | Low : | 2.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VOR ] has closed It is unclear right now based on current values. 41.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.23 - 14.28 | 14.28 - 14.34 |
| Low: | 12.48 - 12.54 | 12.54 - 12.6 |
| Close: | 13.39 - 13.48 | 13.48 - 13.58 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 15 Dec 2025
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Mon, 15 Dec 2025
Vor Biopharma Launches $150 Million Private Placement; Shares Rise - marketscreener.com
Mon, 15 Dec 2025
Vor Bio (Nasdaq: VOR) prices $150M private placement, grants Forbion board seat - Stock Titan
Wed, 10 Dec 2025
Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha
Tue, 09 Dec 2025
Vor Biopharma’s Recent Developments: Stock Impact Analyzed - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 26.8 (%) |
| Shares Short | 226 (K) |
| Shares Short P.Month | 912 (K) |
| EPS | -386.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -246.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -144.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -183 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|